Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have ...

The Federal Trade Commission (FTC) filed a lawsuit Friday against three major prescription drug benefit managers (PBMs) and ...

Recent developments in health include EU approval of Novo's Wegovy for obesity-related heart conditions, the US FDA's nod for ...

The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

Insulin resistance is associated with 31 different diseases and, in women, is also linked to higher odds of an early death, a study of data on hundreds of thousands of people in the UK being ...

Eli Lilly LLY announced positive topline results from two phase III studies, QWINT-1 and QWINT-3, which evaluated efsitora alfa, its once-weekly administered investigational insulin, in adults ...

However, the Federal Trade Commission (FTC) staff has issued a report that focuses on those income claims made by 70 MLM companies. In the report, the FTC staff found many issues with the income ...

Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co.'s experimental once-weekly insulin can lower ...

Eli Lilly (NYSE:LLY) on Thursday announced that its QWINT-1 and QWINT-3 Phase 3 clinical trials for once-weekly insulin efsitora alfa reached the primary endpoints against daily basal insulins ...

(RTTNews) - Eli Lilly and Company (LLY) Thursday announced positive topline results from the QWINT-1 and QWINT-3 phase 3 studies evaluating once weekly basal insulin efsitora alfa in adults with ...

The overall safety of insulin efsitora was similar to that of daily basal insulin therapies. Topline data were announced from 2 studies in the QWINT phase 3 clinical development program ...

An Eli Lilly insulin engineered for once-weekly dosing now has preliminary results from two more pivotal studies showing the injection was comparable to once-daily insulin, a new slate of data ...